<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2679232-A1" country="EP" doc-number="2679232" kind="A1" date="20140101" family-id="48703575" file-reference-id="314654" date-produced="20180823" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146550454" ucid="EP-2679232-A1"><document-id><country>EP</country><doc-number>2679232</doc-number><kind>A1</kind><date>20140101</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-12174472-A" is-representative="YES"><document-id mxw-id="PAPP154824377" load-source="docdb" format="epo"><country>EP</country><doc-number>12174472</doc-number><kind>A</kind><date>20120629</date><lang>EN</lang></document-id><document-id mxw-id="PAPP176648256" load-source="docdb" format="original"><country>EP</country><doc-number>12174472.6</doc-number><date>20120629</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140446235" ucid="EP-12174472-A" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>12174472</doc-number><kind>A</kind><date>20120629</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1988096491" load-source="docdb">A61K  39/04        20060101ALI20121127BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988099854" load-source="docdb">C07K  16/12        20060101ALI20121127BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988120180" load-source="docdb">A61K  35/74        20060101AFI20121127BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-2044368147" load-source="docdb" scheme="CPC">C12N   1/06        20130101 LI20150618BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2044368282" load-source="docdb" scheme="CPC">A61K  39/04        20130101 FI20150620BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2044372432" load-source="docdb" scheme="CPC">C12N   1/20        20130101 LI20150618BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2044374030" load-source="docdb" scheme="CPC">C07K  16/18        20130101 LI20150618BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988139169" load-source="docdb" scheme="CPC">A61K  35/74        20130101 LI20130726BHEP        </classification-cpc><classification-cpc mxw-id="PCL2109735981" load-source="docdb" scheme="CPC">C12N   9/50        20130101 LI20140905BHEP        </classification-cpc><classification-cpc mxw-id="PCL2109736740" load-source="docdb" scheme="CPC">C12Y 302/01017     20130101 LI20140905BHEP        </classification-cpc><classification-cpc mxw-id="PCL2109737830" load-source="docdb" scheme="CPC">C12Y 204/01255     20130101 LI20140905BHEP        </classification-cpc><classification-cpc mxw-id="PCL2109740166" load-source="docdb" scheme="CPC">C07K2319/55        20130101 LA20140905BHEP        </classification-cpc><classification-cpc mxw-id="PCL2109743324" load-source="docdb" scheme="CPC">C12N   9/2462      20130101 LI20140905BHEP        </classification-cpc><classification-cpc mxw-id="PCL2109744083" load-source="docdb" scheme="CPC">C12N   9/1048      20130101 LI20140905BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132183846" lang="DE" load-source="patent-office">Zusammensetzung zur Verwendung bei den Mykobakterien-Impfstoffen</invention-title><invention-title mxw-id="PT132183847" lang="EN" load-source="patent-office">Composition for use in Mycobacteria vaccination</invention-title><invention-title mxw-id="PT132183848" lang="FR" load-source="patent-office">Procédé et appareil d'amélioration d'images</invention-title><citations><patent-citations><patcit mxw-id="PCIT421999374" load-source="docdb" ucid="GB-2015876-A"><document-id format="epo"><country>GB</country><doc-number>2015876</doc-number><kind>A</kind><date>19790919</date></document-id><sources><source name="SEA" category="XA" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242656838" load-source="docdb" ucid="GB-2243611-A"><document-id format="epo"><country>GB</country><doc-number>2243611</doc-number><kind>A</kind><date>19911106</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242656839" load-source="docdb" ucid="WO-2008128065-A2"><document-id format="epo"><country>WO</country><doc-number>2008128065</doc-number><kind>A2</kind><date>20081023</date></document-id><sources><source name="SEA" category="X" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242656840" load-source="docdb" ucid="WO-2010149795-A1"><document-id format="epo"><country>WO</country><doc-number>2010149795</doc-number><kind>A1</kind><date>20101229</date></document-id><sources><source name="SEA" category="A" created-by-npl="N"/></sources></patcit></patent-citations><non-patent-citations><nplcit><text>"Global Tuberculosis Control WHO Report 2010", 2010, WORLD HEALTH ORGANIZATION</text><sources><source mxw-id="PNPL64192261" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>BAE ET AL., BIOINFORMATICS, vol. 21, 2005, pages 2264 - 2270</text><sources><source mxw-id="PNPL64192262" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>BRENNAN, SCIENCE, 1985, pages 229</text><sources><source mxw-id="PNPL64192263" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>BRIERS ET AL., J. BIOCHEM. BIOPHYS METHODS, vol. 70, 2007, pages 531 - 533</text><sources><source mxw-id="PNPL64192264" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>CARROLL J; FIELD D; O'CONNOR PM; COTTER PD; COFFEY A; HILL C; ROSS RP; O'MAHONY J.: "Gene encoded antimicrobial peptides, a template for the design of novel anti-mycobacterial drugs", BIOENG BUGS, vol. L, no. 6, November 2010 (2010-11-01), pages 408 - 12</text><sources><source mxw-id="PNPL64192265" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>CARTER ET AL., BIO/TECHNOLOGY, 1992, pages 10</text><sources><source mxw-id="PNPL64192266" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>DONOVAN DM; LARDEO M; FOSTER-FREY J., FEMS MICROBIOL LETT., vol. 265, no. 1, December 2006 (2006-12-01)</text><sources><source mxw-id="PNPL64192267" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>FILIPA GIL; ANNA E. GRZEGORZEWICZ; MARIA ./OAO CATALIIO; JOÃO VITAL; MICHAEL R. MCNEIL; MADALENA PIMENTEL: "Mycobacteriophage Ms6 LysB specifically targets the outer membrane of Mycobacterium smegmatis", MICROBIOLOGY, vol. 156, May 2010 (2010-05-01), pages 1497 - 1504, XP055199633, DOI: doi:10.1099/mic.0.032821-0</text><sources><source mxw-id="PNPL64192268" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>GEORGE; HERINGA, PROTEIN ENGINEERING, vol. 15, 2003, pages 871 - 879</text><sources><source mxw-id="PNPL64192269" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>GIL ET AL., MICROBIOLOGY, 2010, pages 156</text><sources><source mxw-id="PNPL64192270" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>KIMBERLY M. PAYNE ET AL: "Mycobacteriophage Endolysins: Diverse and Modular Enzymes with Multiple Catalytic Activities", PLOS ONE, vol. 7, no. 3, 28 March 2012 (2012-03-28), pages e34052, XP055041651, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0034052</text><sources><source mxw-id="PNPL64192271" load-source="docdb" name="SEA" category="XD"/></sources></nplcit><nplcit><text>KIMBERLY PAYNE; QINGAN SUN; JAMES SACCHETTINI; GRAHAM F.: "Mycobacteriophage Lysin B is a novel mycolylarabinogalactan esterase", HATFULL MOL MICROBIOL., vol. 73, no. 3, August 2009 (2009-08-01), pages 367 - 381, XP002741811, DOI: doi:10.1111/j.1365-2958.2009.06775.x</text><sources><source mxw-id="PNPL64192272" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>MAARTEN WALMAGH ET AL: "Characterization of Modular Bacteriophage Endolysins from Myoviridae Phages OBP, 201[phi]2-1 and PVP-SE1", PLOS ONE, vol. 7, no. 5, 1 January 2012 (2012-01-01), pages e36991, XP055041652, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0036991</text><sources><source mxw-id="PNPL64192273" load-source="docdb" name="SEA" category="A"/></sources></nplcit><nplcit><text>MELO ET AL., NATURE REVIEWS, MICROBIOLOGY, 2009, pages 245</text><sources><source mxw-id="PNPL64192274" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>MORIMOTO ET AL., JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, 1992, pages 24</text><sources><source mxw-id="PNPL64192275" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>PAYNE ET AL., MOL MICROBIOL, vol. 73, no. 3, 2009</text><sources><source mxw-id="PNPL64192276" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>PAYNE ET AL., MOLECULAR MICROBIOLOGY, vol. 73, no. 3, 2009</text><sources><source mxw-id="PNPL64192277" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>PAYNE KM; HATFULL GF, PLOS ONE, 2012</text><sources><source mxw-id="PNPL64192278" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>PAYNE; HATFULL, PLOS ONE, vol. 7, no. 3, 2012</text><sources><source mxw-id="PNPL64192279" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>SAMBROCK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS</text><sources><source mxw-id="PNPL64192280" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 2001</text><sources><source mxw-id="PNPL64192281" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>SAMBROOK, J. ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR PRESS</text><sources><source mxw-id="PNPL64192282" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>SHIN; JO, IMMUNE NETWORK, vol. 11, no. 5, 2011</text><sources><source mxw-id="PNPL64192283" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>VOLLMER W; JORIS B; CHARLIER P; FOSTER S: "Bacterial peptidoglycan (murein) hydrolases", FEMS MICROBIOL REV., vol. 32, no. 2, March 2008 (2008-03-01), pages 259 - 86, XP055258647, DOI: doi:10.1111/j.1574-6976.2007.00099.x</text><sources><source mxw-id="PNPL64192284" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>ZHOU L; ZHAO Z; LI B; CAI Y; ZHANG S, PROTEIN EXPR PURIF., vol. 64, no. 2, April 2009 (2009-04-01), pages 225 - 230</text><sources><source mxw-id="PNPL64192285" load-source="docdb" name="APP"/></sources></nplcit></non-patent-citations></citations></technical-data><parties><applicants><applicant mxw-id="PPAR918171904" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>LYSANDO AG</last-name><address><country>LI</country></address></addressbook></applicant><applicant mxw-id="PPAR918167485" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>LYSANDO AKTIENGESELLSCHAFT</last-name></addressbook></applicant><applicant mxw-id="PPAR918980025" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Lysando Aktiengesellschaft</last-name><iid>101307967</iid><address><street>Wangerberg 688</street><city>9497 Triesenberg</city><country>LI</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR918136670" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>MILLER STEFAN</last-name><address><country>DE</country></address></addressbook></inventor><inventor mxw-id="PPAR918136205" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>MILLER, STEFAN</last-name></addressbook></inventor><inventor mxw-id="PPAR918983342" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>MILLER, STEFAN</last-name><address><street>Roggenweg 11</street><city>93055 Regensburg</city><country>DE</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR918982899" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Dehmel, Albrecht</last-name><iid>100037386</iid><address><street>Dehmel &amp; Bettenhausen Patentanwälte Herzogspitalstrasse 11</street><city>80331 München</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><designated-states><ep-contracting-states><country mxw-id="DS548909113" load-source="docdb">AL</country><country mxw-id="DS548916328" load-source="docdb">AT</country><country mxw-id="DS548829695" load-source="docdb">BE</country><country mxw-id="DS548858017" load-source="docdb">BG</country><country mxw-id="DS548910527" load-source="docdb">CH</country><country mxw-id="DS548829696" load-source="docdb">CY</country><country mxw-id="DS548907008" load-source="docdb">CZ</country><country mxw-id="DS548909119" load-source="docdb">DE</country><country mxw-id="DS548829697" load-source="docdb">DK</country><country mxw-id="DS548829706" load-source="docdb">EE</country><country mxw-id="DS548894052" load-source="docdb">ES</country><country mxw-id="DS548858018" load-source="docdb">FI</country><country mxw-id="DS548858019" load-source="docdb">FR</country><country mxw-id="DS548909120" load-source="docdb">GB</country><country mxw-id="DS548829707" load-source="docdb">GR</country><country mxw-id="DS548909121" load-source="docdb">HR</country><country mxw-id="DS548907009" load-source="docdb">HU</country><country mxw-id="DS548910528" load-source="docdb">IE</country><country mxw-id="DS548829708" load-source="docdb">IS</country><country mxw-id="DS548858020" load-source="docdb">IT</country><country mxw-id="DS548829709" load-source="docdb">LI</country><country mxw-id="DS548858021" load-source="docdb">LT</country><country mxw-id="DS548916329" load-source="docdb">LU</country><country mxw-id="DS548858022" load-source="docdb">LV</country><country mxw-id="DS548858023" load-source="docdb">MC</country><country mxw-id="DS548916334" load-source="docdb">MK</country><country mxw-id="DS548916335" load-source="docdb">MT</country><country mxw-id="DS548916336" load-source="docdb">NL</country><country mxw-id="DS548907058" load-source="docdb">NO</country><country mxw-id="DS548916337" load-source="docdb">PL</country><country mxw-id="DS548829746" load-source="docdb">PT</country><country mxw-id="DS548811500" load-source="docdb">RO</country><country mxw-id="DS548829747" load-source="docdb">RS</country><country mxw-id="DS548916378" load-source="docdb">SE</country><country mxw-id="DS548909127" load-source="docdb">SI</country><country mxw-id="DS548907059" load-source="docdb">SK</country><country mxw-id="DS548907060" load-source="docdb">SM</country><country mxw-id="DS548894053" load-source="docdb">TR</country></ep-contracting-states><ep-extended-states><ep-extended-state-data><country>BA</country></ep-extended-state-data><ep-extended-state-data><country>ME</country></ep-extended-state-data></ep-extended-states></designated-states></international-convention-data></bibliographic-data><abstract mxw-id="PA128671121" lang="EN" load-source="patent-office"><p id="pa01" num="0001">The present invention relates to a method for the preparation of a mycobacterial lysate comprising the steps of: a) contacting a sample comprising at least one <i>Mycobacterium species</i> with a composition having the activity of degrading the cell wall of a <i>Mycobacterium species,</i> b) incubating the sample for a distinct period, and c) isolating the mycobacterial lysate resulting from step b) thereby obtaining the mycobacterial lysate<i>.</i> Moreover, the present invention relates to the mycobacterial lysate obtained by the method of the present invention and further to a vaccine composition comprising the mycobacterial lysate, an antibody or antibody fragment generated with the mycobacterial lysate or the vaccine, and a pharmaceutical composition comprising the antibody or antibody fragment.</p></abstract><abstract mxw-id="PA128500494" lang="EN" source="EPO" load-source="docdb"><p>The present invention relates to a method for the preparation of a mycobacterial lysate comprising the steps of: a) contacting a sample comprising at least one  Mycobacterium species  with a composition having the activity of degrading the cell wall of a  Mycobacterium species,  b) incubating the sample for a distinct period, and c) isolating the mycobacterial lysate resulting from step b) thereby obtaining the mycobacterial lysate .  Moreover, the present invention relates to the mycobacterial lysate obtained by the method of the present invention and further to a vaccine composition comprising the mycobacterial lysate, an antibody or antibody fragment generated with the mycobacterial lysate or the vaccine, and a pharmaceutical composition comprising the antibody or antibody fragment.</p></abstract><description mxw-id="PDES63956551" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><p id="p0001" num="0001">The present invention relates to a method for the preparation of a mycobacterial lysate comprising the steps of: a) contacting a sample comprising at least one <i>Mycobacterium species</i> with a composition having the activity of degrading the cell wall of a <i>Mycobacterium species,</i> the composition comprising: (a) a first fusion protein including (i) a first endolysin or a first domain, both having a first enzymatic activity, the enzymatic activity being at least one or more of the following: N-acetyl-b-D-muramidase (lysozyme, lytic transglycosylase), N-acetyl-b-D-glucosaminidase, N-acetylmuramoyl-L-alanine amidase, L-alanoyl-D-glutamate (LD) endopeptidase, c-D-glutamyl-meso-diaminopimelic acid (DL) peptidase, L-alanyl-D-iso-glutaminyl-meso-diaminopimelic acid (D-Ala-m-DAP) (DD) endopeptidase, or m-DAP-m-DAP (LD) endopeptidase; and (ii) at least one peptide stretch fused to the N- or C-terminus of the endolysin having the first enzymatic activity or the domain having the first enzymatic activity, wherein the peptide stretch is selected from the group consisting of synthetic amphipathic peptide, synthetic cationic peptide, synthetic polycationic peptide, synthetic hydrophobic peptide, synthetic antimicrobial peptide (AMP) or naturally occurring AMP; and (b) a second fusion protein including (i) a second endolysin or a second domain, both having a second enzymatic activity, the enzymatic activity being at least one or more of the following: lipolytic activity, cutinase, mycolarabinogalactanesterase, or alpha/beta hydrolase; and (ii) at least one peptide stretch fused to the N- or C-terminus of the endolysin having a second enzymatic activity or the domain having the second enzymatic activity, wherein the peptide stretch is selected from the group consisting of synthetic amphipathic peptide, synthetic cationic peptide, synthetic polycationic peptide, synthetic hydrophobic peptide, synthetic antimicrobial peptide (AMP) or naturally occurring AMP; b) incubating the sample for a distinct period, and c) isolating the mycobacterial lysate resulting from step b) thereby obtaining the mycobacterial lysate. Moreover, the present invention relates to the a mycobacterial lysate obtained by the method of the present invention and further to a vaccine composition comprising the mycobacterial lysate, an antibody or antibody fragment generated with the mycobacterial lysate or the vaccine, and a pharmaceutical composition comprising the antibody or antibody fragment.<!-- EPO <DP n="2"> --></p><p id="p0002" num="0002">Mycobacteria are classified as Gram positive bacteria. In comparison to most of the Gram-positive bacteria however, the structure of the cell wall of mycobacteria is different in their composition. The complex structure of the cell wall of mycobacteria consists of a mycolic acid-rich outer membrane which is covalently linked to the arabinogalactan-petidoglycan complex (Hoffmann et al., 2008; Zuber et al., 2008). The mycolic acids are alpha-alkyl, beta-hydroxy C<sub>60-90</sub> fatty acids. The distinct composition of the mycolic acids is dependent on the <i>Mycobacterium species</i> including short saturated alpha, C<sub>20-25</sub>, and a longer meromycolate chain, the beta-hydroxy branch C<sub>60</sub>, comprising doublebonds, cyclopropane rings and oxygenated groups. The outer membrane is linked with esterification to the terminal pentaarabinofuranosyl components of arabinogalactan (<nplcit id="ncit0001" npl-type="s"><text>Payne et al., Molecular Microbiology, 73(3), 2009</text></nplcit>). The arabinogalactan is covalently linked to peptidoglycan. This covalently linked complex is known as mycolyl-arabinogalactan peptidoglycan (mAGP). This mAGP is known as the cell wall core and builds a stable scaffolding to anchor the outer non-covalently associated lipid and glycoplipids including trehalose 6,6'-dimycolate (TDM or cord factor) (<nplcit id="ncit0002" npl-type="s"><text>Gil et al., Microbiology, 156, 2010</text></nplcit>). TDM is a secreted molecule which is important for the pathogenesis of mycobacteria (Brennan, 2003). The cell surface of mycobacteria has the characteristics of a highly hydrophobicity and fastness in view of acids due to the special structure of mAGP and TDM in combination with trehalose 6'-monomycolate. These special properties are leading to the fact that mycobacteria are resistant to dehydration and posses a natural impermeability to nutrients and antibacterial drugs (<nplcit id="ncit0003" npl-type="s"><text>Gil et al., Microbiology, 156, 2010</text></nplcit>).</p><p id="p0003" num="0003"><i>Mycobacterium tuberculosis</i> is the cause for the tuberculosis, an infectious disease which typically affects the lungs. Tuberculosis is a health and life threatening disease. In 2009, 9.4 million new cases of tuberculosis and 1.7 million deaths are counted (<nplcit id="ncit0004" npl-type="b"><text>Global Tuberculosis Control WHO Report 2010. World Health Organization; Geneva: 2010</text></nplcit>). <i>Mycobacterium tuberculosis</i> is spread as a primarily respiratory pathogen. Patients with an active infection can transmit the infection by coughing. A major part of infected human patients are not able to eliminate the bacteria completely. This results in the so called "latent" stage, defining a status, wherein the patient is still infected, but does not show any symptoms of the disease. This latent stage however can change in some patients due to a reactivation of the infection resulting in an active stage of tuberculosis. Typically, an infection with <i>mycobacterium tuberculosis</i> starts with the inhalation of the bacteria, followed by the presentation by antigen-presenting immune cells, such as macrophages or dendritic cells, in the airway. Infected<!-- EPO <DP n="3"> --> macrophages include mycobacteria in intracellular vesicles. However, these vesicles are not accessible for a fusion with lysosomes, which would result in a killing of the mycobacteria. After activation of the infected macrophages with a specific T<sub>H</sub>1-cell, a lysosomal fusion occurs. Further to this first infection step, infected macrophages recruit uninfected macrophages. Thereby a so called granuloma is formed. The structure of such a granuloma, which is also called caseous granuloma because of the "cheese-like" look, comprises macrophages surrounding a necrotic area with adjacent of B and T cells.</p><p id="p0004" num="0004">Vaccination against tuberculosis has been conducted with attenuated mycobacterial vaccination strain (BCG) to achieve a protection against tuberculosis. However, this vaccination has been associated with severe side-effects and complications. Furthermore, the BCG vaccination achieved only a reduced effectiveness. Therefore, this vaccination is not recommended any more. The BGC vaccination was not able to reduce the global spread of tuberculosis. Vaccination against mycobacteria is also difficult since immune responses against the mycobacterial vaccination strains can be attenuated due to non-pathogen mycobacteria species living in soil or drinking water. Having been in contact with these non-pathogen mycobacteria before, reduces immune responses against mycobacteria strains which are foreseen for vaccination. This provides further disadvantages to achieve sufficient immune responses in particular in tropical or subtropical regions.</p><p id="p0005" num="0005">Mycobacteria in general can be classified into several major groups for purpose of diagnosis and treatment: <i>M. tuberculosis</i> complex, which can cause tuberculosis: <i>M. tuberculosis, M. bovis, M. africanum, and M. microti; M. leprae,</i> which causes Hansen's disease or leprosy; Nontuberculous mycobacteria (NTM) define all the other mycobacteria, which can cause pulmonary disease resembling tuberculosis, lymphadenitis, skin disease, or disseminated disease. Mycobacteria not only cause human infections but also animal infections as well, e.g. <i>Mycobacterium avium, Mycobacterium avium subsp. paratuberculosis, Mycobacerium bovis.</i></p><p id="p0006" num="0006">Mycobacteriophages are a subgroup of bacteriophages, which are bacterial viruses, which target mycobacterial hosts. In view of the special structure and composition of the cell wall of mycobacteria, it is necessary for the mycobacteriophages to degrade the peptidoglycan layer and further to lyse the mycolic acid-rich outer membrane attached to the mAGP complex.<!-- EPO <DP n="4"> --></p><p id="p0007" num="0007">Various types of agents having bactericidal or bacteriostatic activity are known, e.g. antibiotics, endolysins, antimicrobial peptides and defensins. Increasingly microbial resistance to antibiotics, however, is creating difficulties in treating more and more infections caused by bacteria.</p><p id="p0008" num="0008">Endolysins are peptidoglycan hydrolases encoded by bacteriophages (or bacterial viruses). They are synthesized during late gene expression in the lytic cycle of phage multiplication and mediate the release of progeny virions from infected cells through degradation of the bacterial peptidoglycan. They are either ß(1,4)-glycosylases, transglycosylases, amidases or endopeptidases. Antimicrobial application of endolysins was already suggested in <patcit id="pcit0001" dnum="GB2243611A"><text>1991 by Gasson (GB2243611</text></patcit>). Although the killing capacity of endolysins has been known for a long time, the use of these enzymes as antibacterials was ignored due to the success and dominance of antibiotics. Only after the appearance of multiple antibiotic resistant bacteria this concept of combating human pathogens with endolysins received interest. A compelling need to develop totally new classes of antibacterial agents emerged and endolysins used as 'enzybiotics' - a hybrid term of 'enzymes' and 'antibiotics' - seem to meet this need. In 2001, Fischetti and coworkers demonstrated for the first time the therapeutic potential of bacteriophage Cl endolysin towards group A streptococci (Nelson et al., 2001). Since then many publications have established endolysins as an attractive and complementary alternative to control bacterial infections, particularly by Gram positive bacteria. Subsequently different endolysins against other Gram positive pathogens such as <i>Streptococcus pneumoniae</i> (Loeffler et al., 2001), <i>Bacillus anthracis</i> (Schuch et al., 2002), <i>S. agalactiae</i> (Cheng et al., 2005) and <i>Staphylococcus aureus</i> (Rashel et al., 2007) have proven their efficacy as enzybiotics.</p><p id="p0009" num="0009">Distinct endolysins have been identified in mycobacteriophages (<nplcit id="ncit0005" npl-type="s"><text>Payne and Hatfull, Plos ONE, 7(3), 2012</text></nplcit>; <nplcit id="ncit0006" npl-type="s"><text>Payne et al., Mol Microbiol, 73(3), 2009</text></nplcit>). These particular endolysins are able to break down the mycobacterial cell wall characterized by the mycol-rich mycobacterial outer membrane attached to an arabinogalactan layer which is in turn linked to the peptidoglycan. These particular phage endolysins can be assigned to two groups, (i) enzymes that cleave the peptidoglycan, and (ii) enzymes that cleave the mycolic acid and arabinogalactan layer.<!-- EPO <DP n="5"> --></p><p id="p0010" num="0010">Antimicrobial peptides (AMPs) represent an important component of the innate immunity against infections against bacteria. Several antimicrobial peptides have been identified which possess an effect against mycobacteria. These antimicrobial peptides are involved not only in the killing of mycobacteria but also in the modulation of the immune defense in form of the secretion of cytokines and chemokines (<nplcit id="ncit0007" npl-type="s"><text>Shin and Jo, Immune Network, 11(5), 2011</text></nplcit>).</p><p id="p0011" num="0011">Antimicrobial peptides (AMPs) represent a wide range of short, cationic or amphipathic, gene encoded peptide antibiotics that can be found in virtually every organism. Different AMPs display different properties, and many peptides in this class are being intensively researched not only as antibiotics, but also as templates for cell penetrating peptides. Despite sharing a few common features (e.g., cationicity, amphipathicity and short size), AMP sequences vary greatly, and at least four structural groups (α-helical, β-sheet, extended and looped) have been proposed to accommodate the diversity of the observed AMP conformations. Likewise, several modes of action as antibiotics have been proposed, and it was shown e.g. that the primary target of many of these peptides is the cell membrane whereas for other peptides the primary target is cytoplasmic invasion and disruption of core metabolic functions. AMPs may become concentrated enough to exhibit cooperative activity despite the absence of specific target binding; for example, by forming a pore in the membrane, as is the case for most AMPs. However, this phenomenon has only been observed in model phospholipid bilayers, and in some cases, AMP concentrations in the membrane that were as high as one peptide molecule per six phospholipid molecules were required for these events to occur. These concentrations are close to, if not at, full membrane saturation. As the minimum inhibitory concentration (MIC) for AMPs are typically in the low micromolar range, scepticism has understandably arisen regarding the relevance of these thresholds and their importance <i>in vivo</i> (<nplcit id="ncit0008" npl-type="s"><text>Melo et al., Nature reviews, Microbiology, 2009, 245</text></nplcit>).</p><p id="p0012" num="0012">Cathelicidins are a family of AMPs which are derived from leukocytes and epithelial cells. Currently, the only identified human cathelicidin is hCAP-18/LL-37. Immunstimulatory effects have been reported for cathelicidins (<nplcit id="ncit0009" npl-type="s"><text>Shin and Jo, Immune Network, 11(5), 2011</text></nplcit>).</p><p id="p0013" num="0013">Defensins are a large family of small, cationic or amphipathic, cysteine- and arginine-rich antimicrobial peptides, found in both vertebrates and invertebrates. Defensins are divided into five groups according to the spacing pattern of cysteines: plant, invertebrate, α-, β-, and θ-defensins. The latter three are mostly found in mammals. α -defensins are proteins found in<!-- EPO <DP n="6"> --> neutrophils and intestinal epithelia. β-defensins are the most widely distributed and are secreted by leukocytes and epithelial cells of many kinds. θ-defensins have been rarely found so far e.g. in leukocytes of rhesus macaques. Defensins are active against bacteria, fungi and many enveloped and nonenveloped viruses. However, the concentrations needed for efficient killing of bacteria are mostly high, i.e. in the µ-molar range. Activity of many peptides may be limited in presence of physiological salt conditions, divalent cations and serum. Depending on the content of hydrophobic amino acid residues defensins also show haemolytic activity.</p><p id="p0014" num="0014">Hepcidin is a cationic amphipathic bactericidal peptide which is primarily produced in the liver. The expression of Hepcidin is induced during infectious and inflammatory conditions. Crucially, Hepcidin is expressed in macrophages after infection with intracellular pathogens <i>Mycobacterium avium</i> and <i>Mycobacterium tuberculosis.</i> Further, hepcidin causes damage to <i>Mycobacterium tuberculosis</i> and thus exerts immediate antimycobacterial activity (<nplcit id="ncit0010" npl-type="s"><text>Shin and Jo, Immune Network, 11(5), 2011</text></nplcit>).</p><p id="p0015" num="0015">Since there are currently no satisfying vaccination compositions available and in view of the difficulties to treat tuberculosis effectively there is a need for new vaccination compositions.</p><p id="p0016" num="0016">Thus, the technical problem underlying the present invention is the provision of a new vaccine composition as well as methods for the preparation thereof.</p><p id="p0017" num="0017">This technical problem is solved by the subject-matter defined in the claims.</p><p id="p0018" num="0018">The term "protein" as used herein refers to a linear polymer of amino acid residues linked by peptide bonds in a specific sequence. The amino-acid residues of a protein may be modified by e.g. covalent attachments of various groups such as carbohydrates and phosphate. Other substances may be more loosely associated with the protein, such as heme or lipid, giving rise to the conjugated proteins which are also comprised by the term "protein" as used herein. The protein may be folded in different ways. The various ways in which the protein fold have been elucidated, are in particular with regard to the presence of alpha helices and beta-pleated sheets. The term "protein" as used herein refers to all four classes of proteins being all-alpha, all-beta, alpha/beta and alpha plus beta. Moreover, the term "protein" refers to a complex, wherein the complex refers to a homomer.<!-- EPO <DP n="7"> --></p><p id="p0019" num="0019">The term "fusion protein" as used herein refers to an expression product resulting from the fusion of different nucleic acid sequences. Such a protein may be produced, e.g., in recombinant DNA expression systems. Moreover, the term "fusion protein" as used herein refers to a fusion of a first amino acid sequence having an enzymatic activity, e.g. an endolysin, with a second and a third amino acid sequence. The second amino acid sequence is preferably a peptide stretch, in particular selected from the group consisting of cationic, polycationic, hydrophobic, amphipathic peptides, and antimicrobial peptides. A third amino acid sequence is a protein transduction domain. Preferably, said second and third amino acid sequence is foreign to and not substantially homologous with any domain of the first amino acid sequence. Moreover, the fusion proteins of the present invention also refer to an expression product resulting from the fusion of at least three nucleic acid sequences.</p><p id="p0020" num="0020">The term "peptide stretch" as used herein refers to any kind of peptide linked to a protein such as an endolysin. In particular the term "peptide stretch" as used herein refers to a peptide stretch selected from the group consisting of cationic, polycationic, hydrophobic, amphipathic peptides, and antimicrobial peptides (AMP), in particular synthetic amphipathic peptide, synthetic cationic peptide, synthetic polycationic peptide, synthetic hydrophobic peptide, synthetic antimicrobial peptide (AMP) or naturally occurring AMP. In the context of the present invention, AMP are understood as peptides, which provide antimycobacterial activity.</p><p id="p0021" num="0021">However, a peptide stretch in the meaning of the present invention does not refer to His-tags, preferably His<sub>5</sub>-tags, His<sub>6</sub>-tags, His<sub>7</sub>-tags, His<sub>8</sub>-tags, His<sub>9</sub>-tags, His<sub>10</sub>-tags, His<sub>11</sub>-tags, His<sub>12</sub>-tags, His<sub>16</sub>-tags and His<sub>20</sub>-tags, Strep-tags, Avi-tags, Myc-tags, Gst-tags, JS-tags, cystein-tags, FLAG-tags or other tags known in the art, thioredoxin or maltose binding proteins (MBP). The term "tag" in contrast to the term "peptide stretch" as used herein refers to a peptide which can be useful to facilitate expression and/or affinity purification of a polypeptide, to immobilize a polypeptide to a surface or to serve as a marker or a label moiety for detection of a polypeptide e.g. by antibody binding in different ELISA assay formats as long as the function making the tag useful for one of the above listed facilitation is not caused by the positively charge of said peptide. However, the His<sub>6</sub>-tag may, depending on the respective pH, also be positively charged, but is used as affinity purification tool as it binds to immobilized divalent cations and is not used as a peptide stretch according to the present invention.<!-- EPO <DP n="8"> --></p><p id="p0022" num="0022">The term "peptide" as used herein refers to short polypeptides consisting of from about 2 to about 100 amino acid residues, more preferably from about 4 to about 50 amino acid residues, more preferably from about 5 to about 30 amino acid residues, wherein the amino group of one amino acid residue is linked to the carboxyl group of another amino acid residue by a peptide bond. A peptide may have a specific function. A peptide can be a naturally occurring peptide or a synthetically designed and produced peptide. The peptide can be, for example, derived or removed from a native protein by enzymatic or chemical cleavage, or can be prepared using conventional peptide synthesis techniques (e.g., solid phase synthesis) or molecular biology techniques (see <nplcit id="ncit0011" npl-type="b"><text>Sambrook, J. et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1989</text></nplcit>)). Preferred naturally occurring peptides are e.g. antimicrobial peptides and defensins. Preferred synthetically produced peptides are e.g. polycationic, amphipathic or hydrophobic peptides. A peptide in the meaning of the present invention does not refer to His-tags, Strep-tags, thioredoxin or maltose binding proteins (MBP) or the like, which are used to purify or locate proteins.</p><p id="p0023" num="0023">The term "enzymatic activity" as used herein refers to the effect exerted by one or more enzyme(s) or enzyme like substance(s). An enzymatic activity refers in particular to the effects which are exerted by endolysins. The term "enzymatic activity" refers further in particular to the effect of distinct group of enzyme or enzymatic substances which are having the activity of degrading the cell wall of a <i>Mycobacterium species.</i> A group of these enzymes with this distinct characteristics are named as Lysin A (LysA), of the peptidoglycan-cleavage group, which are known or are proposed to cleave (<nplcit id="ncit0012" npl-type="s"><text>Payne and Hatfull, Plos ONE, 7(3), 2012</text></nplcit>; <nplcit id="ncit0013" npl-type="s"><text>Payne et al., Mol Microbiol, 73(3), 2009</text></nplcit>):
<ul><li>N-acetyl-b-D-muramidase (lysozyme, lytic transglycosylase);</li><li>N-acetyl-b-D-glucosaminidase;</li><li>N-acetylmuramoyl-L-alanine amidase;</li><li>L-alanoyl-D-glutamate (LD) endopeptidase;</li><li>c-D-glutamyl-meso-diaminopimelic acid (DL) peptidase;</li><li>D-Ala-m-DAP (DD) endopeptidase; and</li><li>m-DAP-m-DAP (LD) endopeptidase.</li></ul></p><p id="p0024" num="0024">A further group of enzymes are named as Lysin B (LysB). These enzymes hydrolyze the linkage of the mycolic acids to the peptidoglycan-arabinogalactan complex and comprise at least the following or other lipolytic activities:<!-- EPO <DP n="9"> -->
<ul><li>Esterase (mycolarabinogalactanesterase)</li><li>Cutinase</li><li>α/β hydrolase</li></ul></p><p id="p0025" num="0025">LysB like proteins are described e.g. in <nplcit id="ncit0014" npl-type="s"><text>Mycobacteriophage Lysin B is a novel mycolylarabinogalactan esterase Kimberly Payne, Qingan Sun, James Sacchettini, Graham F. Hatfull Mol Microbiol. 2009 August; 73(3): 367-381</text></nplcit><i>;</i> <nplcit id="ncit0015" npl-type="s"><text>Mycobacteriophage Ms6 LysB specifically targets the outer membrane of Mycobacterium smegmatis Filipa Gil, Anna E. Grzegorzewicz, Maria João Catalão, João Vital, Michael R. McNeil, Madalena Pimentel Microbiology. 2010 May; 156(Pt 5): 1497-1504</text></nplcit><i>.</i></p><p id="p0026" num="0026">A person skilled in the art is able to identify an enzymatic activity as mentioned above with applying a suitable test setting for the distinct enzyme or enzymatic activity.</p><p id="p0027" num="0027">The term "endolysin" as used herein refers to an enzyme which is a peptidoglycan hydrolase naturally encoded by bacteriophages or bacterial viruses and which is suitable to hydrolyse bacterial cell walls. According to the present invention "endolysins" may derive from mycobacteriophages. Thus, "endolysins" are in particular enzymes such as Lysin A, LysA, or Lysin A like enzymes or Lysin B, LysB, or Lys B like enzymes. "Endolysins" comprise at least one "enzymatically active domain" (EAD) having at least one or more of the following activities: N-acetyl-b-D-muramidase (lysozyme, lytic transglycosylase), N-acetyl-b-D-glucosaminidase, N-acetyl-muramoyl-L-alanine-amidase (amidase) peptidase, L-alanoyl-D-glutamate (LD) endopeptidase, L-alanyl-D-iso-glutaminyl-meso-diaminopimelic acid (D-Ala-m-DAP) (DD) endopeptidase, or m-DAP-m-DAP (LD) endopeptidase. Furthermore, the EAD is having at least one or more of the following activities: lipolytic activity, cutinase, mycolarabinogalactanesterase, or alpha/beta hydrolase. In addition, the endolysins may contain also regions which are enzymatically inactive, and bind to the cell wall of the host bacteria, the so-called CBDs (cell wall binding domains). The endolysin may contain two or more CBDs. Generally, the cell wall binding domain is able to bind different components on the surface of bacteria. Preferably, the cell wall binding domain is a peptidoglycan binding domain and binds to the bacteria's peptidoglycan structure. The different domains of an endolysin can be connected by a domain linker.<!-- EPO <DP n="10"> --></p><p id="p0028" num="0028">The term "domain linker" as used herein refers to an amino acid sequence functioning to connect single protein domains with one another. As a rule domain linkers form no or only few regular secondary structure like α-helices or ß-sheets and can occupy different conformations with the respective structural context. Methods to detect domain linker and properties of linker sequences are well known in the art as e.g. described in <nplcit id="ncit0016" npl-type="s"><text>Bae et al., 2005, Bioinformatics, 21, 2264-2270</text></nplcit> or <nplcit id="ncit0017" npl-type="s"><text>George &amp; Heringa, 2003, Protein Engineering, 15, 871-879</text></nplcit>.</p><p id="p0029" num="0029">The term "deletion" as used herein refers to the removal of 1, 2, 3, 4, 5 or more amino acid residues from the respective starting sequence.</p><p id="p0030" num="0030">The term "insertion" or "addition" as used herein refers to the insertion or addition of 1, 2, 3, 4, 5 or more amino acid residues to the respective starting sequence.</p><p id="p0031" num="0031">The term "substitution" as used herein refers to the exchange of an amino acid residue located at a certain position for a different one.</p><p id="p0032" num="0032">The term "cell wall" as used herein refers to all components that form the outer cell enclosure in particular of a Mycobacterium and thus guarantee their integrity. In particular, the term "cell wall" as used herein refers to in particular to the arabinogalactan layer an the mycolic acid layer of Mycobacteria, but also to membranes or additional layers deposited or attached to the mycolic acid layer, such as capsule-like material, outer protein layer or slimes.</p><p id="p0033" num="0033">The term "EAD" as used herein refers to the enzymatically active domain of an endolysin. The EAD is responsible for hydrolysing bacterial peptidoglycans. It exhibits at least one enzymatic activity of an endolysin. The EAD can also be composed of more than one enzymatically active module. The term "EAD" is used herein synonymously with the term "catalytic domain".</p><p id="p0034" num="0034">As used herein, the term "cationic peptide" refers to a synthetic peptide having positively charged amino acid residues. Preferably a cationic peptide has a pKa-value of 9.0 or greater. Typically, at least four of the amino acid residues of the cationic peptide can be positively charged, for example, lysine or arginine. "Positively charged" refers to the side chains of the amino acid residues which have a net positive charge at about physiological conditions. The term "cationic peptide" as used herein refers also to polycationic peptides.<!-- EPO <DP n="11"> --></p><p id="p0035" num="0035">The term "polycationic peptide" as used herein refers to a synthetically produced peptide composed of mostly positively charged amino acid residues, in particular lysine and/or arginine residues. A peptide is composed of mostly positively charged amino acid residues of at least about 20, 30, 40, 50, 60, 70, 75, 80, 85, 90, 95 or about 100% of the amino acid residues are positively charged amino acid residues, in particular lysine and/or arginine residues. The amino acid residues being not positively charged amino acid residues can be neutrally charged amino acid residues and/or negatively charged amino acid residues and/or hydrophobic amino acid residues. Preferably the amino acid residues being not positively charged amino acid residues are neutrally charged amino acid residues, in particular serine and/or glycine.</p><p id="p0036" num="0036">The term "antimicrobial peptide" (AMP) as used herein refers to any naturally occurring peptide that has microbicidal and/or microbistatic activity in particular against a <i>Mycobacterium species.</i> Thus, the term "antimicrobial peptide" as used herein relates in particular to any peptide having anti-bacterial, anti-infectious, anti-infective and/or germicidal, microbicidal, or bactericidal properties.</p><p id="p0037" num="0037">The antimicrobial peptide may be a member of the RNAse A super family, a defensin, cathelicidin, granulysin, histatin, psoriasin, dermicidine or hepcidin. The antimicrobial peptide may be naturally occurring in insects, fish, plants, arachnids, vertebrates or mammals. Preferably the antimicrobial peptide may be naturally occurring in insects, fish, plants, arachnids, vertebrates or mammals. Preferably the antimicrobial peptide may be naturally occurring in radish, silk moth, wolf spider, frog, preferably in <i>Xenopus laevis, Rana</i> frogs, more preferably in <i>Rana catesbeiana,</i> toad, preferably Asian toad <i>Bufo bufo gargarizans,</i> fly, preferably in <i>Drosophila,</i> more preferably in <i>Drosophila melanogaster,</i> in <i>Aedes aegypti,</i> in honey bee, bumblebee, preferably in <i>Bombus pascuorum,</i> flesh fly, preferably in <i>Sarcophaga peregrine,</i> scorpion, horseshoe crab, catfish, preferably in <i>Parasilurus asotus,</i> cow, pig, sheep, porcine, bovine, monkey and human.</p><p id="p0038" num="0038">The term "amphiphatic peptide" as used herein refers to synthetic peptides having both hydrophilic and hydrophobic functional groups. Preferably, the term "amphiphatic peptide" as used herein refers to a peptide having a defined arrangement of hydrophilic and hydrophobic<!-- EPO <DP n="12"> --> groups e.g. amphipathic peptides may be e.g. alpha helical, having predominantly non polar side chains along one side of the helix and polar residues along the remainder of its surface.</p><p id="p0039" num="0039">The term "hydrophobic group" as used herein refers to chemical groups such as amino acid side chains which are substantially water insoluble, but soluble in an oil phase, with the solubility in the oil phase being higher than that in water or in an aqueous phase. In water, amino acid residues having a hydrophobic side chain interact with one another to generate a nonaqueous environment. Examples of amino acid residues with hydrophobic side chains are valine, isoleucine, leucine, methionine, phenylalanine, tryptophan, cysteine, alanine, tyrosine, histidine, threonin, serine, proline and glycine residues.</p><p id="p0040" num="0040">The term "autolysins" refers to enzymes related to endolysins but encoded by bacteria and involved in e.g. cell division. An overview of autolysins is can be found in "Bacterial peptidoglycan (murein) hydrolases. <nplcit id="ncit0018" npl-type="s"><text>Vollmer W, Joris B, Charlier P, Foster S. FEMS Microbiol Rev. 2008 Mar;32(2):259-86</text></nplcit>".</p><p id="p0041" num="0041">The term "bacteriocin" as used herein refers to protein-like, polypeptide-like or peptide-like substances which are able to inhibit the growth of other bacteria. Some bacteriocins are capable of degrading bacterial cell walls like Lysostaphin (degrading <i>Staphylococcus</i> cell walls), Mutanolysin (degrading <i>Streptococcus</i> cell walls) and Enterolysin (degrading <i>Enterococcus</i> cell walls). Preferably said growth inhibition is specifically by means of absorption of said other bacteria to specific receptors of the bacteriocin. A further group of bacteriocins are Nisin-like peptides (Gene encoded antimicrobial peptides, a template for the design of novel anti-mycobacterial drugs. <nplcit id="ncit0019" npl-type="s"><text>Carroll J, Field D, O'Connor PM, Cotter PD, Coffey A, Hill C, Ross RP, O'Mahony J. Bioeng Bugs. 2010 Nov-Dec;1(6):408-12</text></nplcit>). In general, bacteriocins are produced by microorganisms. However, the term "bacteriocin" as used herein refers both to an isolated form procuded by a microorganism or to a synthetically produced form, and refers also to variants which substantially retain the activities of their parent bacteriocins, but whose sequences have been altered by insertion or deletion of one or more amino acid residues.</p><p id="p0042" num="0042">The present invention relates to method for the preparation of a mycobacterial lysate comprising the steps of: a) contacting a sample comprising at least one <i>Mycobacterium species</i> with a composition having the activity of degrading the cell wall of a <i>Mycobacterium<!-- EPO <DP n="13"> --> species,</i> the composition comprising: (a) a first fusion protein including (i) a first endolysin or a first domain, both having a first enzymatic activity, the enzymatic activity being at least one or more of the following: N-acetyl-b-D-muramidase (lysozyme, lytic transglycosylase), N-acetyl-b-D-glucosaminidase, N-acetylmuramoyl-L-alanine amidase, L-alanoyl-D-glutamate (LD) endopeptidase, c-D-glutamyl-meso-diaminopimelic acid (DL) peptidase, L-alanyl-D-iso-glutaminyl-meso-diaminopimelic acid (D-Ala-m-DAP) (DD) endopeptidase, or m-DAP-m-DAP (LD) endopeptidase; and (ii) at least one peptide stretch fused to the N- or C-terminus of the endolysin having the first enzymatic activity or the domain having the first enzymatic activity, wherein the peptide stretch is selected from the group consisting of synthetic amphipathic peptide, synthetic cationic peptide, synthetic polycationic peptide, synthetic hydrophobic peptide, synthetic antimicrobial peptide (AMP) or naturally occurring AMP; and (b) a second fusion protein including (i) a second endolysin or a second domain, both having a second enzymatic activity, the enzymatic activity being at least one or more of the following: lipolytic activity, cutinase, mycolarabinogalactanesterase, or alpha/beta hydrolase; and (ii) at least one peptide stretch fused to the N- or C-terminus of the endolysin having a second enzymatic activity or the domain having the second enzymatic activity, wherein the peptide stretch is selected from the group consisting of synthetic amphipathic peptide, synthetic cationic peptide, synthetic polycationic peptide, synthetic hydrophobic peptide, synthetic antimicrobial peptide (AMP) or naturally occurring AMP; b) incubating the sample for a distinct period, and c) isolating the mycobacterial lysate resulting from step b) thereby obtaining the mycobacterial lysate.</p><p id="p0043" num="0043">The composition according to the present invention comprising a first and a second fusion protein allows a degradation of the mycobacterial cell wall in a distinct pattern. This pattern results in a mycobacterial lysate which has advantageous and beneficial properties. The degradation of mycobacteria using the composition of the present invention allows a mild and standardized generation of mycobacterial lysate. This lysate is the result of completely degraded and thus killed mycobacteria. The mycobacterial lysate of the present invention therefore provides fragments, comprising peptide and sugar structures, of the degraded mycobacteria which are characterized to be useful as antigens to provoke a good immune response within a vaccine composition. Furthermore, since the mycobacterial lysate does not include any components of living mycobacteria, the mycobacterial lysate is also safe comparable to a vaccine composition including attenuated mycobacteria.<!-- EPO <DP n="14"> --></p><p id="p0044" num="0044">In a preferred embodiment of the composition of the present invention the first endolysin is Lysin A (LysA) or the first enzymatic activity of the first domain is exerted by Lysin A (LysA) or Lysin A like enzymes and the second endolysin is Lysin B (LysB) or the second enzymatic activity of the second domain is exerted by Lysin B (LysB) or Lysin B like enzymes.</p><p id="p0045" num="0045">Examples for the first and second endolysins or the first and second enzymatic activity of the first and second domain are listed in the following table 1.
<tables id="tabl0001" num="0001"><table frame="all"><title>Table 1:</title><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="35mm"/><colspec colnum="2" colname="col2" colwidth="33mm"/><colspec colnum="3" colname="col3" colwidth="32mm"/><colspec colnum="4" colname="col4" colwidth="33mm"/><colspec colnum="5" colname="col5" colwidth="35mm"/><thead><row><entry valign="top"><b>Mycobacteriophage</b></entry><entry valign="top"><b>endolysin/ domain</b></entry><entry valign="top"><b>type of endolysin or domain</b></entry><entry valign="top"><b>amino acid sequence</b></entry><entry valign="top"><b>nucleic acid sequence</b></entry></row></thead><tbody><row><entry>TM4</entry><entry>TM4gp29</entry><entry>Lysin A</entry><entry>SEQ ID NO:1</entry><entry>SEQ ID NO:2</entry></row><row><entry>Bxz2</entry><entry>Bxz2gp11</entry><entry>Lysin A</entry><entry>SEQ ID NO:3</entry><entry>SEQ ID NO:4</entry></row><row><entry>D29</entry><entry>D29gp 10</entry><entry>Lysin A</entry><entry>SEQ ID NO:5</entry><entry>SEQ ID NO:6</entry></row><row><entry>L5</entry><entry>L5gp10</entry><entry>Lysin A</entry><entry>SEQ ID NO:7</entry><entry>SEQ ID NO:8</entry></row><row><entry>TM4</entry><entry>TM4gp30</entry><entry>Lysin B</entry><entry>SEQ ID NO:9</entry><entry>SEQ ID NO:10</entry></row><row><entry>Bxz2</entry><entry>Bxz2gp12</entry><entry>Lysin B</entry><entry>SEQ ID NO:11</entry><entry>SEQ ID NO:12</entry></row><row><entry>D29</entry><entry>D29gp 12</entry><entry>Lysin B</entry><entry>SEQ ID NO:13</entry><entry>SEQ ID NO:14</entry></row><row><entry>L5</entry><entry>L5gp12</entry><entry>Lysin B</entry><entry>SEQ ID NO:15</entry><entry>SEQ ID NO:16</entry></row></tbody></tgroup></table></tables></p><p id="p0046" num="0046">In a preferred embodiment the first and the second enzymatic activity of the first and second fusion protein of the composition is exerted by enzymes derived from mycobacteriophages selected from the group consisting of TM4, D29, L5, and Bxz2.</p><p id="p0047" num="0047">In a further preferred embodiment the peptide stretch of the first and second fusion protein of the composition of the present invention comprises an antimicrobial peptide (AMP), the AMP being selected from the group consisting of Cathelicidins (hCAP-18/LL37), alpha defensins, beta defensins, hepcidin, NK-2, and Ci-MAM-A24.<!-- EPO <DP n="15"> --></p><p id="p0048" num="0048">Examples for antimicrobial peptides according to the present invention are listed in the following table 2.
<tables id="tabl0002" num="0002"><table frame="all"><title>Table 2:</title><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="26mm"/><colspec colnum="2" colname="col2" colwidth="90mm"/><colspec colnum="3" colname="col3" colwidth="39mm"/><thead><row><entry><b>Peptid</b></entry><entry><b>amino acid sequence</b></entry><entry><b>nucleic acid sequence</b></entry></row></thead><tbody><row><entry/><entry><img id="ib0001" file="imgb0001.tif" wi="86" he="9" img-content="dna" img-format="tif"/></entry><entry>SEQ ID NO:18</entry></row><row><entry>LL-37</entry><entry>SEQ ID NO:17</entry><entry/></row><row><entry/><entry>DCYCRIPACIAGERRYGTCIYQGRLWAFCC</entry><entry>SEQ ID NO:20</entry></row><row><entry>alpha-defensin</entry><entry>SEQ ID NO:19</entry><entry/></row><row><entry/><entry><img id="ib0002" file="imgb0002.tif" wi="86" he="9" img-content="dna" img-format="tif"/></entry><entry>SEQ ID NO:22</entry></row><row><entry>beta-defensin</entry><entry>SEQ ID NO:21</entry><entry/></row><row><entry/><entry>DTHFPICIFCCGCCHRSKCGMCCKT</entry><entry>SEQ ID NO:24</entry></row><row><entry>Hepcidin</entry><entry>SEQ ID NO:23</entry><entry/></row><row><entry/><entry>KILRGVCKKIMRTFLRRISKDILTGKK;</entry><entry>SEQ ID NO:26</entry></row><row><entry>NK-2</entry><entry>SEQ ID NO:25</entry><entry/></row><row><entry/><entry>WRSLGRTLLRLSHALKPLARRSGW</entry><entry>SEQ ID NO:28</entry></row><row><entry>Ci-MAM-A24</entry><entry>SEQ ID NO:27</entry><entry/></row></tbody></tgroup></table></tables></p><p id="p0049" num="0049">In a further preferred embodiment the composition of the present invention is having activity of degrading the cell wall of a <i>Mycobacterium species</i> which is selected from the group consisting of <i>Mycobacterium tuberculosis, Mycobacterium microti, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium canettii, Mycobacterium pinnipedii, Mycobacterium caprae, Mycobacterium mungi, Mycobacterium leprae, Mycobacterium ulcerans, Mycobacterium xenopi, Mycobacterium shottsii, Mycobacterium avium, Mycobacterium avium subsp. paratuberculosis, Mycobacterium paratuberculosis, Mycobacterium intracellulare, Mycobacterium smegmatis, Mycobacterium kansasii, Mycobacterium terrae, Mycobacterium nonchromogenicum, Mycobacterium gordonae, and Mycobacterium triviale.</i></p><p id="p0050" num="0050">In a preferred embodiment of the present invention the method is conducted, wherein step c) comprises High Performance Liquid chromatography (HPLC), Fast protein liquid<!-- EPO <DP n="16"> --> chromatography (FPLC), filtration techniques, field flow fractionation, centrifugation or other techniques known as state in the art for the separation of biomolecules from bacterial lysates.</p><p id="p0051" num="0051">In a preferred embodiment of the method of the present invention, the first fusion protein of the composition exhibits an amino acid sequence selected from the group consisting SEQ ID NO:29, 31, 33, 35, 37, 39, and 41, and wherein the second fusion of the composition protein exhibits an amino acid sequence selected from the group consisting SEQ ID NO:43, 45, 47, 49, 51, 53, and 55.</p><p id="p0052" num="0052">Specific examples of fusion proteins according to the present invention are listed in the following table.
<tables id="tabl0003" num="0003"><table frame="all"><title>Table 3:</title><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="63mm"/><colspec colnum="2" colname="col2" colwidth="37mm"/><colspec colnum="3" colname="col3" colwidth="39mm"/><thead><row><entry valign="top"><b>First fusion protein</b></entry><entry valign="top"><b>amino acid sequence</b></entry><entry valign="top"><b>nucleic acid sequence</b></entry></row></thead><tbody><row><entry>TM4gp29/LL-37</entry><entry>SEQ ID NO:29</entry><entry>SEQ ID NO:30</entry></row><row><entry>TM4gp29/LL-37</entry><entry>SEQ ID NO:31</entry><entry>SEQ ID NO:32</entry></row><row><entry>Bzx2gp 11/alpha-defensin</entry><entry>SEQ ID NO:33</entry><entry>SEQ ID NO:34</entry></row><row><entry>alpha-defensin/Bzx2gp11</entry><entry>SEQ ID NO:35</entry><entry>SEQ ID NO:36</entry></row><row><entry>alpha-defensin/Bzx2gp 11/alpha-defensin</entry><entry>SEQ ID NO:37</entry><entry>SEQ ID NO:38</entry></row><row><entry>beta-defensin/L5gp10</entry><entry>SEQ ID NO:39</entry><entry>SEQ ID NO:40</entry></row><row><entry>beta-defensin/Hepcidin/L5gp10</entry><entry>SEQ ID NO:41</entry><entry>SEQ ID NO:42</entry></row></tbody></tgroup><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="63mm"/><colspec colnum="2" colname="col2" colwidth="37mm"/><colspec colnum="3" colname="col3" colwidth="39mm"/><thead><row><entry valign="top"><b>Second fusion protein</b></entry><entry valign="top"><b>amino acid sequence</b></entry><entry valign="top"><b>nucleic acid sequence</b></entry></row></thead><tbody><row><entry>TM4gp30/LL-37</entry><entry>SEQ ID NO:43</entry><entry>SEQ ID NO:44</entry></row><row><entry>TM4gp30/LL-37</entry><entry>SEQ ID NO:45</entry><entry>SEQ ID NO:46</entry></row><row><entry>D29gp12/alpha-defensin</entry><entry>SEQ ID NO:47</entry><entry>SEQ ID NO:48</entry></row><row><entry>alpha-defensin/D29gp12</entry><entry>SEQ ID NO:49</entry><entry>SEQ ID NO:50</entry></row><row><entry>alpha-defensin/D29gp 12/alpha-defensin</entry><entry>SEQ ID NO:51</entry><entry>SEQ ID NO:52</entry></row><row><entry>beta-defensin/D29gp 12</entry><entry>SEQ ID N0:53</entry><entry>SEQ ID NO:54</entry></row><row><entry>beta-defensin/Hepcidin/L5gp12</entry><entry>SEQ ID NO:55</entry><entry>SEQ ID NO:56</entry></row></tbody></tgroup></table></tables></p><p id="p0053" num="0053">In another preferred embodiment of the present invention the enzymes, such as endolysins, autolysins and bacteriocins of the first and second fusion protein according to the present<!-- EPO <DP n="17"> --> invention comprise modifications and/or alterations of the amino acid sequences. Such alterations and/or modifications may comprise mutations such as deletions, insertions and additions, substitutions or combinations thereof and/or chemical changes of the amino acid residues, e.g. biotinylation, acetylation, pegylation, chemical changes of the amino-, SH- or carboxyl- groups. Said endolysins, autolysins and bacteriocins of the fusion protein according to the present invention exhibit the lytic activity of the respective wild-type endolysin, autolysin and bacteriocin. However, said activity can be the same, higher or lower as the activity of the respective wild-type endolysin, autolysin and bacteriocin. Said activity can be about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190 or about 200% of the activity of the respective wild-type endolysin, autolysin and bacteriocin or even more. The activity can be measured by assays well known in the art by a person skilled in the art as e.g. the plate lysis assay or the liquid lysis assay which are e.g. described in <nplcit id="ncit0020" npl-type="s"><text>Briers et al., J. Biochem. Biophys Methods 70: 531-533, (2007</text></nplcit><i>),</i> <nplcit id="ncit0021" npl-type="s"><text>Donovan DM, Lardeo M, Foster-Frey J. FEMS Microbiol Lett. 2006 Dec;265(1</text></nplcit><i>),</i> <nplcit id="ncit0022" npl-type="s"><text>Payne KM, Hatfull GF PLoS One, 2012</text></nplcit><i>.</i></p><p id="p0054" num="0054">The peptide stretch and the PTD of the fusion proteins according to the present invention may be linked to the endolysin or the domain having an enzymatic activity by additional amino acid residues e.g. due to cloning reasons. Preferably, said additional amino acid residues may be not recognized and/or cleaved by proteases. Preferably the peptide stretch and the PTD may be linked to the endolysin or the domain having an enzymatic activity by at least 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid residues. In a preferred embodiment the peptide stretch is fused to the N- or C-terminus of the endolysin or the domain having an enzymatic activity by the additional amino acid residues glycine, serine, and alanine (Gly-Ser-Ala). Moreover, the PTD is located on the N-terminus or on the C-Terminus of the first fusion protein or of the second fusion protein according to the invention.</p><p id="p0055" num="0055">The PTD may further comprise additional amino acids on its N- or C-terminus. Preferably the peptide stretch or the PTD comprise the amino acid methionine (Met), or methionine, glycine and serine (Met-Gly-Ser). In another preferred embodiment the first peptide stretch is linked to the N-terminus of the enzyme by the additional amino acid residues, in particular glycine and serine (Gly-Ser) and the second peptide stretch is linked to the N-terminus of the first peptide stretch by the additional amino acid residues, in particular glycine and serine (Gly-Ser). In another preferred embodiment the first peptide stretch is linked to the C-terminus of<!-- EPO <DP n="18"> --> the enzyme by the additional amino acid residues, in particular glycine and serine (Gly-Ser) and the second peptide stretch is linked to the C-terminus of the first peptide stretch by the additional amino acid residues, in particular glycine and serine (Gly-Ser).</p><p id="p0056" num="0056">Within the first and second fusion protein according to the present invention the peptide stretch and the PTD are preferably covalently bound to the endolysin or to the domain, both having enzymatic activity. Preferably, the peptide stretch and the PTD consist of at least 5, more preferably at least of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or at least 100 amino acid residues. Especially preferred are peptide stretches and PTDs comprising about 5 to about 100 amino acid residues, about 5 to about 50 or about 5 to about 30 amino acid residues. More preferred are peptide stretches and PTDs comprising about 6 to about 42 amino acid residues, about 6 to about 39 amino acid residues, about 6 to about 38 amino acid residues, about 6 to about 31 amino acid residues, about 6 to about 25 amino acid residues, about 6 to about 24 amino acid residues, about 6 to about 22 amino acid residues, about 6 to about 21 amino acid residues, about 6 to about 20 amino acid residues, about 6 to about 19 amino acid residues, about 6 to about 16 amino acid residues, about 6 to about 14 amino acid residues, about 6 to about 12 amino acid residues, about 6 to about 10 amino acid residues or about 6 to about 9 amino acid residues.</p><p id="p0057" num="0057">Preferably, the peptide stretches are no tag such as a His-tag, Strep-tag, Avi-tag, Myc-tag, Gst-tag, JS-tag, cystein-tag, FLAG-tag or other tags known in the art and no thioredoxin or maltose binding proteins (MBP). However, the first and second fusion protein according to the present invention may comprise in addition such tag or tags.</p><p id="p0058" num="0058">More preferably the peptide stretches have the function to lead the first and second fusion protein of the composition of the present invention through the outer membrane but may have activity or may have no or only low activity when administered without being fused to the endolysin or the domain, both having enzymatic activity. The function to lead the first and second fusion protein through the outer membrane of mycobacteria is caused by the potential of the outer membrane or mycolic acid/arabinogalactan or LPS disrupting or permeabilising or destabilizing activity of said peptide stretches in combination with the PTDs and the<!-- EPO <DP n="19"> --> endolysins or the domains. Such outer membrane or LPS disrupting or permeabilising or destabilizing activity of the peptide stretches may be determined in a method as follows: The bacteria cells to be treated are cultured in liquid medium or on agar plates. Then the bacteria cell concentration in the liquid medium is determined photometrically at OD600 nm or the colonies on the agar plates are counted, respectively. Now, the bacteria cells in liquid medium or on the plates are treated with a first and second fusion protein according to the invention. After incubation the bacteria cell concentration in the liquid medium is determined photometrically at OD600 nm or the colonies on the agar plates are counted again. If the first and second fusion protein exhibits such outer membrane or LPS disrupting or permeabilising or destabilizing activity, the bacteria cells are lysed due to the treatment with the fusion protein and thus, the bacteria cell concentration in the liquid medium or the number of the bacteria colonies on the agar plate is reduced. Thus, the reduction in bacteria cell concentration or in the number of bacteria colonies after treatment with the first and second fusion protein is indicative for an outer membrane or LPS disrupting or permeabilising or destabilizing activity of the first and second fusion protein.</p><p id="p0059" num="0059">Fusion proteins are constructed by linking at least three nucleic acid sequences using standard cloning techniques as described e.g. by <nplcit id="ncit0023" npl-type="b"><text>Sambrook et al. 2001, Molecular Cloning: A Laboratory Manual</text></nplcit>. Such a protein may be produced, e.g., in recombinant DNA expression systems. Such fusion proteins according to the present invention can be obtained by fusing the nucleic acids for endolysin and the respective peptide stretches.</p><p id="p0060" num="0060">A further subject-matter of the present invention relates to an isolated nucleic acid molecule encoding the first fusion protein of the composition of to the present invention or to an isolated nucleic acid molecule encoding the second fusion protein of the composition of the present invention.</p><p id="p0061" num="0061">Preferably the isolated nucleic acid molecule encoding the first fusion protein of the composition of to the present invention is selected from the group consisting of SEQ ID NO:30, 32, 34, 36, 38, 40, and 42, and wherein the second fusion of the composition protein exhibits an amino acid sequence selected from the group consisting SEQ ID NO:44, 46, 48, 50, 52, 54, and 56.<!-- EPO <DP n="20"> --></p><p id="p0062" num="0062">The present invention further relates to a vector comprising a nucleic acid molecule according to the present invention. Said vector may provide for the constitutive or inducible expression of said fusion protein according to the present invention.</p><p id="p0063" num="0063">The invention also relates to a method for obtaining said first and second fusion protein of the composition of the present invention from a micro-organism, such as a genetically modified suitable host cell which expresses said fusion proteins. Said host cell may be a microorganism such as bacteria or yeast or an animal cell as e.g. a mammalian cell, in particular a human cell. In one embodiment of the present invention the host cell is a <i>Pichia pastoris</i> cell. The host may be selected due to mere biotechnological reasons, e.g. yield, solubility, costs, etc. but may be also selected from a medical point of view, e.g. a non-pathological bacteria or yeast, human cells.</p><p id="p0064" num="0064">Another subject-matter of the present invention relates to a method for genetically transforming a suitable host cell in order to obtain the expression of the first and second fusion protein of the composition according to the invention, wherein the host cell is genetically modified by the introduction of a genetic material encoding said fusion proteins into the host cell and obtain their translation and expression by genetic engineering methods well known by a person skilled in the art.</p><p id="p0065" num="0065">A further subject-matter of the invention relates to a mycobacterial lysate according to the present invention which is obtained by a method according to the present invention. The method for the preparation of the mycobacterial lysate foresees using of a composition comprising a first and second fusion protein. The composition allows a good degradation of the mycobacterial cell wall which results in a distinct patter of fragments of the mycobacteria with the mycobacterial lysate. The mycobacterial lysate obtained with the method of the present invention provides fragments, comprising peptide and sugar structures, of the degraded mycobacteria.</p><p id="p0066" num="0066">A further subject-matter of the invention relates to a vaccine composition for preventing a disease caused by a <i>Mycobacterium species</i> comprising the mycobacterial lysate of the present invention.<!-- EPO <DP n="21"> --></p><p id="p0067" num="0067">According to the present invention, the mycobacterial lysate is the active ingredient within the vaccine composition. The vaccine composition according to the present invention provides the advantages to be safe and to provoke good immune response due to the distinct pattern of fragments present within the mycobacterial lysate.</p><p id="p0068" num="0068">In a preferred embodiment of the present invention, the vaccine composition is further comprising an adjuvant and/or a pharmaceutical acceptable carrier.</p><p id="p0069" num="0069">A further subject-matter of the present invention relates to an antibody or an antibody fragment generated by the administration of the mycobacterial lysate according to the present invention or the vaccine composition according to the present invention to a subject.</p><p id="p0070" num="0070">Different antibody molecules are known in the art. Several types of immunglobulins are IgG, IgM, IgD, IgA or IgE. Further artificially defined antibodies such as bispecific antibodies are further examples.</p><p id="p0071" num="0071">Several techniques are know to generate antibody fragments (e.g. <nplcit id="ncit0024" npl-type="s"><text>Morimoto etal., Journal of Biochemical and Biophysical Methods 24, 1992</text></nplcit>; <nplcit id="ncit0025" npl-type="s"><text>Brennan at al., Science, 229, 1985</text></nplcit>). These fragments can also be produced directly by using recombinant cells. Antibody phage libraries are a tool to isolate specific antibody fragments. Fab'-SH fragments can be isolated directly form a <i>E</i>. <i>coli</i> culture and chemically coupled to form F(ab')<sub>2</sub> fragments (<nplcit id="ncit0026" npl-type="s"><text>Carter et al., Bio/Technology 10, 1992</text></nplcit>). Moreover, F(ab')<sub>2</sub> fragments can be isolated directly from host cell culture. Further techniques for the production of antibody fragments will be apparent to a person skilled in the art. A single chain Fv fragment (scFv) is a further example of an antibody fragment.</p><p id="p0072" num="0072">The antibodies or antibody fragments according to the present invention possess improved binding abilities. Therefore, these antibodies and antibody fragments are useful tools for research and diagnostic.</p><p id="p0073" num="0073">Preferably, the antibody of the present invention is a monoclonal or polyclonal antibody.<!-- EPO <DP n="22"> --></p><p id="p0074" num="0074">A further subject-matter of the present invention relates to a pharmaceutical composition comprising the antibody or the antibody fragment according to the present invention for use in preventing or treating an infectious disease caused by a <i>Mycobacterium species.</i></p><p id="p0075" num="0075">Further scope of applicability of the present invention will become apparent from the detailed description given hereinafter, however, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.</p><p id="p0076" num="0076">The following examples explain the present invention but are not considered to be limiting. Unless indicated differently, molecular biological standard methods were used, as e.g., described by <nplcit id="ncit0027" npl-type="b"><text>Sambrock et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York</text></nplcit>.</p><heading id="h0001">Example 1: <u>Cloning, expression and purification of the respective fusion proteins modified with various peptide stretches at the N-terminus or the C-terminus.</u></heading><heading id="h0002"><u>Proteins</u></heading><p id="p0077" num="0077">TM4gp29 according to SEQ ID NO: 1 is a Lys A-type endolysin originating from <i>Mycobacteria</i> phage TM4. The endolysin TM4gp29 is encoded by the nucleic acid molecule according to SEQ ID NO: 2. The nucleic acid molecule according to SEQ ID NO: 2 was synthetically produced with a BamH I (5'-GGA TCC-3') restriction site at the 5'-end of the nucleic acid molecule and an Xho I (5'-CTC GAG-3') restriction site at the 3'-end of the nucleic acid molecule.</p><p id="p0078" num="0078">Bxz2gp11 according to SEQ ID NO: 3 is a Lys A-type endolysin originating from <i>Mycobacteria</i> phage Bxz2. The endolysin Bxz2gp11 is encoded by the nucleic acid molecule according to SEQ ID NO: 4. The nucleic acid molecule according to SEQ ID NO: 4 was synthetically produced with a BamH I (5'-GGA TCC-3') restriction site at the 5'-end of the<!-- EPO <DP n="23"> --> nucleic acid molecule and an Xho I (5'-CTC GAG-3') restriction site at the 3'-end of the nucleic acid molecule.</p><p id="p0079" num="0079">D29gp10 according to SEQ ID NO: 5 is a Lys A-type endolysin originating from <i>Mycobacteria</i> phage D29. The endolysin D29gp10 is encoded by the nucleic acid molecule according to SEQ ID NO: 6. The nucleic acid molecule according to SEQ ID NO: 6 was synthetically produced with a BamH I (5'-GGA TCC-3') restriction site at the 5'-end of the nucleic acid molecule and an Xho I (5'-CTC GAG-3') restriction site at the 3'-end of the nucleic acid molecule.</p><p id="p0080" num="0080">L5gp10 according to SEQ ID NO: 7 is a Lys A-type endolysin originating from <i>Mycobacteria</i> phage L5. The endolysin L5gp10 is encoded by the nucleic acid molecule according to SEQ ID NO: 8. The nucleic acid molecule according to SEQ ID NO: 8 was synthetically produced with a BamH I (5'-GGA TCC-3') restriction site at the 5'-end of the nucleic acid molecule and an Xho I (5'-CTC GAG-3') restriction site at the 3'-end of the nucleic acid molecule.</p><p id="p0081" num="0081">TM4gp30 according to SEQ ID NO: 9 is a Lys B-type endolysin originating from <i>Mycobacteria</i> phage TM4. The endolysin TM4gp30 is encoded by the nucleic acid molecule according to SEQ ID NO: 10. The nucleic acid molecule according to SEQ ID NO: 10 was synthetically produced with a BamH I (5'-GGA TCC-3') restriction site at the 5'-end of the nucleic acid molecule and an Xho I (5'-CTC GAG-3') restriction site at the 3'-end of the nucleic acid molecule.</p><p id="p0082" num="0082">Bxz2gp12 according to SEQ ID NO: 11 is a Lys B-type endolysin originating from <i>Mycobacteria</i> phage Bxz2. The endolysin Bxz2gp12 is encoded by the nucleic acid molecule according to SEQ ID NO: 12. The nucleic acid molecule according to SEQ ID NO: 12 was synthetically produced with a BamH I (5'-GGA TCC-3') restriction site at the 5'-end of the nucleic acid molecule and an Xho I (5'-CTC GAG-3') restriction site at the 3'-end of the nucleic acid molecule.</p><p id="p0083" num="0083">D29gp12 according to SEQ ID NO: 13 is a Lys B-type endolysin originating from <i>Mycobacteria</i> phage D29. The endolysin D29gp12 is encoded by the nucleic acid molecule according to SEQ ID NO: 14. The nucleic acid molecule according to SEQ ID NO: 14 was synthetically produced with a BamH I (5'-GGA TCC-3') restriction site at the 5'-end of the<!-- EPO <DP n="24"> --> nucleic acid molecule and an Xho I (5'-CTC GAG-3') restriction site at the 3'-end of the nucleic acid molecule.</p><p id="p0084" num="0084">L5gp12 according to SEQ ID NO: 15 is a Lys B-type endolysin originating from <i>Mycobacteria</i> phage L5. The endolysin L5gp12 is encoded by the nucleic acid molecule according to SEQ ID NO: 16. The nucleic acid molecule according to SEQ ID NO: 16 was synthetically produced with a BamH I (5'-GGA TCC-3') restriction site at the 5'-end of the nucleic acid molecule and an Xho I (5'-CTC GAG-3') restriction site at the 3'-end of the nucleic acid molecule.</p><p id="p0085" num="0085">The following peptide stretches in table 1 were used for production of fusion proteins with the endolysins above:
<tables id="tabl0004" num="0004"><table frame="all"><title>Table 1:</title><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="26mm"/><colspec colnum="2" colname="col2" colwidth="29mm"/><colspec colnum="3" colname="col3" colwidth="36mm"/><thead><row><entry valign="top">Peptide stretch</entry><entry valign="top">Protein sequence</entry><entry valign="top">Nucleic acid sequence</entry></row></thead><tbody><row><entry>LL-37</entry><entry>SEQ ID NO: 17</entry><entry>SEQ ID NO: 18</entry></row><row><entry>Alpha-defensin</entry><entry>SEQ ID NO: 19</entry><entry>SEQ ID NO: 20</entry></row><row><entry>Beta-defensin</entry><entry>SEQ ID NO: 21</entry><entry>SEQ ID NO: 22</entry></row><row><entry>Hepcidin</entry><entry>SEQ ID NO: 23</entry><entry>SEQ ID NO: 24</entry></row><row><entry>NK-2</entry><entry>SEQ ID NO: 25</entry><entry>SEQ ID NO: 26</entry></row><row><entry>Ci-MAM-A24</entry><entry>SEQ ID NO: 27</entry><entry>SEQ ID NO: 28</entry></row></tbody></tgroup></table></tables></p><p id="p0086" num="0086">The nucleic acid molecules encoding the respective peptide stretches were synthetically produced with a Nde I (5'-CAT ATG-3') restriction site at the 5'-end of the nucleic acid molecule and a BamH I (5'-GGA TCC-3') restriction site at the 3'-end of the nucleic acid molecule.</p><p id="p0087" num="0087">Fusion proteins are constructed by linking at least two nucleic acid sequences using standard cloning techniques as described e.g. by <nplcit id="ncit0028" npl-type="b"><text>Sambrook et al. 2001, Molecular Cloning: A Laboratory Manual</text></nplcit>. Therefore the nucleic acid molecules encoding the peptide stretches were cleaved in a digest with the respective restriction enzymes Nde I and BamH I and in case of the nucleic acid molecule encoding the peptide stretch for ligation with the proteins the digest was performed with the restriction enzymes Nco I and BamH I. Subsequently the cleaved nucleic acids encoding the peptide stretches were ligated into the pET21 b expression vector<!-- EPO <DP n="25"> --> (Novagen, Darmstadt, Germany), which was also cleaved in a digest with the respective restriction enzymes Nde I and BamH I before. The cleaved nucleic acid molecule encoding the peptide stretch for ligation with toxic proteins was ligated into a modified pET32 b expression vector (unmodified vector obtainable from Novagen, Darmstadt, Germany), which was also cleaved in a digest with the respective restriction enzymes Nco I and BamH I before. The modification of the pET32b expression vector refers to the deletion of the sequence encoding a S-tag and the central His-tag.</p><p id="p0088" num="0088">Afterwards, the nucleic acid molecules encoding the proteins were cleaved in a digest with the restriction enzyme BamH I and Xho I, so that the proteins could be ligated into the pET21b expression vector (Novagen, Darmstadt, Germany) and the modified pET32 b expression vector, respectively, which were also cleaved in a digest with the respective restriction enzymes BamH I and Xho I before.</p><p id="p0089" num="0089">In the case of the peptide stretch, which was introduced by PCR to the C-terminus of the proteins, the resulting fusion protein has a His-tag on the N-terminus, wherein the His-tag is linked to the N-terminus by a linker. For the cloning of the respective nucleic acid molecules the pET32 b expression vector (Novagen, Darmstadt, Germany) was used.</p><p id="p0090" num="0090">Thus, the nucleic acid molecule encoding the peptide stretch is ligated into the respective vector at the 5'-end of the nucleic acid molecule encoding the respective enzyme. Moreover, the nucleic acid molecule encoding the respective enzyme is ligated into the respective plasmid, so that a nucleic acid molecule encoding a His-tag consisting of six histidine residues is associated at the 3'-end of the nucleic acid molecule encoding the endolysin.</p><p id="p0091" num="0091">As some fusion proteins may either be toxic upon expression in bacteria, or not homogenous due to protein degradation, the strategy might be to express these fusion proteins fused or linked to other additional proteins. Example for these other additional protein is thioredoxin, which was shown to mediate expression of toxic antimicrobial peptides in <i>E.coli</i> (TrxA mediating fusion expression of antimicrobial peptide CM4 from multiple joined genes in Escherichia coli. <nplcit id="ncit0029" npl-type="s"><text>Zhou L, Zhao Z, Li B, Cai Y, Zhang S. Protein Expr Purif. 2009 Apr;64(2):225-230</text></nplcit>). In the case of the fusion protein consisting of the N-terminal peptide stretch and the protein, the peptide was ligated into the modified pET32 b expression vector, so that an additional thioredoxin is associated at the 5'-end of the peptide. The thioredoxin<!-- EPO <DP n="26"> --> could be removed from the expressed fusion protein by the use of enterokinase, therefore between the nucleic acid molecule encoding the peptide and the one encoding the thioredoxin is an enterokinase restriction site introduced.</p><p id="p0092" num="0092">The sequence of the endolysin-peptide-fusions was controlled via DNA-sequencing and correct clones were transformed into <i>E.coli</i> BL21(DE3) or <i>E.coli</i> BL21(DE3) pLysS (Novagen, Darmstadt, Germany) for protein expression.</p><p id="p0093" num="0093">Recombinant expression of the fusion proteins according to SEQ ID NO: xx to xx is performed in <i>E. coli</i> BL21 (DE3) cells (Novagen, Darmstadt, Germany). The cells were growing until an optical density of OD600nm of 0.5-0.8 was reached. Then the expression of the fusion protein was induced with 1 mM IPTG (isopropylthiogalactoside) and the expression was performed at 37°C for a period of 4 hours, alternatively an overnight expression at 16°C was performed.</p><p id="p0094" num="0094"><i>E.coli</i> BL21 cells were harvested by centrifugation for 20 min at 6000g and disrupted via sonication on ice. Soluble and insoluble fraction of the E.coli crude extract were separated by centrifugation (Sorvall, SS34, 30 min, 15 000 rpm). All proteins were purified by Ni<sup>2+</sup> affinity chromatography (Akta FPLC, GE Healthcare) using the C-terminal 6xHis-tag, encoded by the pET21b or pET32b vectors.</p><p id="p0095" num="0095">Toxic proteins were expressed using a modified pET32b vector (S-tag and central His-tag deleted), which fuses thioredoxin on the N-terminus of the proteins of interest. The vector also contains an enterokinase cleavage site right before the protein of interest. This site allows the proteolytic cleavage between thioredoxin and the protein of interest, which can purified via the remaining C-terminal His-tag. Expressed fusion proteins were not toxic to the host resulting in high yields of produced protein. For antimicrobial function of the fusion protein it was necessary to remove the thioredoxin by proteolytic cleavage. Therefore the fusion protein was cleaved with 2-4 units/mg recombinant enterokinase (Novagen, Darmstadt, Germany) to remove the thioredoxin following the protocol provided by the manufacturer. After enterokinase cleavage the fusion protein was purified via His-tag purification as described below.</p><p id="p0096" num="0096">The Ni<sup>2+</sup> affinity chromatography is performed in 4 subsequent steps, all at room temperature:<!-- EPO <DP n="27"> -->
<ol><li><i>1. Equilibration</i> of the <i>Histrap FF 5 ml</i> column (GE Healthcare) with up to 10 column volumes of Washing Buffer (20 mM imidazole, 1 M NaCl and 20 mM Hepes on pH 7.4) at a flow rate of 3-5 ml/min.</li><li><i>2. Loading</i> of the total lysate (with wanted fusion protein) on the <i>Histrap FF 5 ml</i> column at a flow rate of 3-5 ml/min.</li><li>3. Washing of the column with up to 10 column volumes of Washing Buffer to remove unbound sample followed by a second washing step with 10% Elution buffer (500 mM imidazole, 0.5 M NaCl and 20 mM Hepes on pH 7.4)at a flow rate of 3-5 ml/min.</li><li>4. Elution of bounded fusion proteins from the column with a linear gradient of 4 column volumes of Elution Buffer (500 mM imidazole, 0.5 M NaCl and 20 mM Hepes on pH 7.4) to 100% at a flow rate of 3-5 ml/min.</li></ol></p><p id="p0097" num="0097">Purified stock solutions of fusion proteins in Elution Buffer (20 mM Hepes pH 7.4; 0.5 M NaCl; 500 mM imidazole) were at least 90% pure as determined visually on SDS-PAGE gels (data not shown).</p><p id="p0098" num="0098">Lysin A like activity was controlled in a Chloroform assay. Escherichia coli BL21 transformed with the respective Lysin A variant were grown at 37°C in LB broth supplemented with 100 mg/mL ampicillin to an OD600 nm of 0.5 and then induced with a final concentration of 1mM IPTG. One hour after induction, 2% chloroform was added to the cell suspension and OD600nm was monitored. Chloroform permeabilizes the inner membrane, thus replacing the holin function, and allows the putative lysin to reach its target in the peptidoglycan layer. The reduction in OD600nm after addition of chloroform to 10mL of induced clones was recorded.</p><p id="p0099" num="0099">Lysin B like activity was controlled by enzymatic assays for lipolytic activity like from those described by Payne et al. 2009. Briefly one milliliter of p-nitrophenyl substrates (50 mM) (Sigma) was incubated with 1 mg of the lysine B variants, or 5 ml of a mock purified sample (derived from pET21 or pET32 containing cells) in buffer (20 mM Tris-HCl pH 8.0, 100 mM NaCl, 0.1% Triton X-100) at room temperature for 30 min. Release of p-nitrophenol was determined by measuring absorbance at 420 nm (A420).<!-- EPO <DP n="28"> --></p><heading id="h0003"><u>EXAMPLE 2: Lysing activity of fusion proteins modified with various peptide stretches on the N-terminus or the C-terminus.</u></heading><p id="p0100" num="0100">Mycobacteria were grown to an OD600 of 1.0. If necessary, clumps were dispersed by passing the bacterial suspension several times through a 25-gauge needle. A volume of 500 ml was added to 3 ml top agar containing 1 mM CaCl<sub>2</sub> and poured onto 7H10 agar plates enriched with 1 mM CaCl<sub>2</sub> and OADC (oleic acid, BSA, dextrose and catalase; Difco). For each modified protein, a serial dilution was prepared in storage buffer. Twenty-microlitre volumes of the original stock and of each dilution were pipetted onto the bacterial lawn, and the spots were allowed to dry completely. Plates were incubated for 4 days for the fast growing mycobacteria, and for up to 6 weeks for the slow growing strains, at the optimal temperature for the individual strain.
<tables id="tabl0005" num="0005"><table frame="all"><title>Table: Lytic activity of the fusion proteins</title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="33mm"/><colspec colnum="2" colname="col2" colwidth="37mm"/><colspec colnum="3" colname="col3" colwidth="81mm"/><colspec colnum="4" colname="col4" colwidth="15mm"/><thead><row><entry valign="top"><b>First fusion protein</b></entry><entry valign="top"><b>Second fusion protein</b></entry><entry valign="top"><b>Composition comprising the first and second fusion protein</b></entry><entry valign="top"><b>control</b></entry></row></thead><tbody><row><entry>SEQ ID NO 29: -</entry><entry>SEQ ID NO 43: -</entry><entry>SEQ ID NO 29 + SEQ ID NO 43: ++</entry><entry>-</entry></row><row><entry>SEQ ID NO 31: -</entry><entry>SEQ ID NO 45: -</entry><entry>SEQ ID NO 31 + SEQ ID NO 45: ++</entry><entry>-</entry></row><row><entry>SEQ ID NO 33: -</entry><entry>SEQ ID NO 47: -</entry><entry>SEQ ID NO 33 + SEQ ID NO 47: +</entry><entry>-</entry></row><row><entry>SEQ ID NO 35: -</entry><entry>SEQ ID NO: 49: -</entry><entry>SEQ ID NO 35 + SEQ ID NO 49: +</entry><entry>-</entry></row><row><entry>SEQ ID NO 37: -</entry><entry>SEQ ID NO 51: <i>-</i></entry><entry>SEQ ID NO 37 + SEQIDNO51:++</entry><entry>-</entry></row><row><entry>SEQ ID NO 39: -</entry><entry>SEQ ID NO 53: -</entry><entry>SEQ ID NO 39 + SEQ ID NO 53: +</entry><entry>-</entry></row><row><entry>SEQ ID NO 41: -</entry><entry>SEQ ID NO 55: -</entry><entry>SEQ ID NO 41 + SEQ ID NO 55: ++</entry><entry>-</entry></row></tbody></tgroup><!-- EPO <DP n="29"> --><tgroup cols="4" rowsep="0"><colspec colnum="1" colname="col1" colwidth="33mm"/><colspec colnum="2" colname="col2" colwidth="37mm"/><colspec colnum="3" colname="col3" colwidth="81mm"/><colspec colnum="4" colname="col4" colwidth="15mm"/><tbody><row><entry namest="col1" nameend="col4" align="justify">Abbreviations: - no activity; +: small halo; ++: large halo. "halo" defines the area on the bacterial plate where mycobacteria lysis occurred.</entry></row></tbody></tgroup></table></tables></p><heading id="h0004"><u>EXAMPLE 3: Preparation of mycobacterial lysates.</u></heading><p id="p0101" num="0101">Mycobacteria were grown to an OD600 of 1.0. Then a buffered composition of LysA like and LysB like fusion proteins according to SEQ ID NO: 29 and SEQ ID NO: 43, since this composition provided very good mycobacterial lysing activity, was added and the bacteria were incubated for at least 60 minutes at room temperature. If needed the bacterial lysate was purified further.<!-- EPO <DP n="30"> -->
<img id="ib0003" file="imgb0003.tif" wi="130" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="31"> -->
<img id="ib0004" file="imgb0004.tif" wi="125" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="32"> -->
<img id="ib0005" file="imgb0005.tif" wi="143" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="33"> -->
<img id="ib0006" file="imgb0006.tif" wi="148" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="34"> -->
<img id="ib0007" file="imgb0007.tif" wi="132" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="35"> -->
<img id="ib0008" file="imgb0008.tif" wi="146" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="36"> -->
<img id="ib0009" file="imgb0009.tif" wi="143" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="37"> -->
<img id="ib0010" file="imgb0010.tif" wi="132" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="38"> -->
<img id="ib0011" file="imgb0011.tif" wi="146" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="39"> -->
<img id="ib0012" file="imgb0012.tif" wi="148" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="40"> -->
<img id="ib0013" file="imgb0013.tif" wi="132" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="41"> -->
<img id="ib0014" file="imgb0014.tif" wi="146" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="42"> -->
<img id="ib0015" file="imgb0015.tif" wi="132" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="43"> -->
<img id="ib0016" file="imgb0016.tif" wi="146" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="44"> -->
<img id="ib0017" file="imgb0017.tif" wi="148" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="45"> -->
<img id="ib0018" file="imgb0018.tif" wi="146" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="46"> -->
<img id="ib0019" file="imgb0019.tif" wi="148" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="47"> -->
<img id="ib0020" file="imgb0020.tif" wi="146" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="48"> -->
<img id="ib0021" file="imgb0021.tif" wi="130" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="49"> -->
<img id="ib0022" file="imgb0022.tif" wi="143" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="50"> -->
<img id="ib0023" file="imgb0023.tif" wi="147" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="51"> -->
<img id="ib0024" file="imgb0024.tif" wi="143" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="52"> -->
<img id="ib0025" file="imgb0025.tif" wi="143" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="53"> -->
<img id="ib0026" file="imgb0026.tif" wi="132" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="54"> -->
<img id="ib0027" file="imgb0027.tif" wi="132" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="55"> -->
<img id="ib0028" file="imgb0028.tif" wi="146" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="56"> -->
<img id="ib0029" file="imgb0029.tif" wi="143" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="57"> -->
<img id="ib0030" file="imgb0030.tif" wi="132" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="58"> -->
<img id="ib0031" file="imgb0031.tif" wi="146" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="59"> -->
<img id="ib0032" file="imgb0032.tif" wi="146" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="60"> -->
<img id="ib0033" file="imgb0033.tif" wi="126" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="61"> -->
<img id="ib0034" file="imgb0034.tif" wi="130" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="62"> -->
<img id="ib0035" file="imgb0035.tif" wi="143" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="63"> -->
<img id="ib0036" file="imgb0036.tif" wi="125" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="64"> -->
<img id="ib0037" file="imgb0037.tif" wi="126" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="65"> -->
<img id="ib0038" file="imgb0038.tif" wi="151" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="66"> -->
<img id="ib0039" file="imgb0039.tif" wi="147" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="67"> -->
<img id="ib0040" file="imgb0040.tif" wi="125" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="68"> -->
<img id="ib0041" file="imgb0041.tif" wi="143" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="69"> -->
<img id="ib0042" file="imgb0042.tif" wi="146" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="70"> -->
<img id="ib0043" file="imgb0043.tif" wi="126" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="71"> -->
<img id="ib0044" file="imgb0044.tif" wi="147" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="72"> -->
<img id="ib0045" file="imgb0045.tif" wi="126" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="73"> -->
<img id="ib0046" file="imgb0046.tif" wi="151" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="74"> -->
<img id="ib0047" file="imgb0047.tif" wi="147" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="75"> -->
<img id="ib0048" file="imgb0048.tif" wi="127" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="76"> -->
<img id="ib0049" file="imgb0049.tif" wi="148" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="77"> -->
<img id="ib0050" file="imgb0050.tif" wi="125" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="78"> -->
<img id="ib0051" file="imgb0051.tif" wi="143" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="79"> -->
<img id="ib0052" file="imgb0052.tif" wi="148" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="80"> -->
<img id="ib0053" file="imgb0053.tif" wi="146" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="81"> -->
<img id="ib0054" file="imgb0054.tif" wi="148" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="82"> -->
<img id="ib0055" file="imgb0055.tif" wi="146" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="83"> -->
<img id="ib0056" file="imgb0056.tif" wi="148" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="84"> -->
<img id="ib0057" file="imgb0057.tif" wi="146" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="85"> -->
<img id="ib0058" file="imgb0058.tif" wi="146" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="86"> -->
<img id="ib0059" file="imgb0059.tif" wi="143" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="87"> -->
<img id="ib0060" file="imgb0060.tif" wi="146" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="88"> -->
<img id="ib0061" file="imgb0061.tif" wi="143" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="89"> -->
<img id="ib0062" file="imgb0062.tif" wi="155" he="73" img-content="dna" img-format="tif"/></p></description><claims mxw-id="PCLM56977489" lang="EN" load-source="patent-office"><!-- EPO <DP n="90"> --><claim id="c-en-0001" num="0001"><claim-text>A method for the preparation of a mycobacterial lysate comprising the steps of:
<claim-text>a) contacting a sample comprising at least one <i>Mycobacterium species</i> with a composition having the activity of degrading the cell wall of a <i>Mycobacterium species,</i> the composition comprising:
<claim-text>(a) a first fusion protein including
<claim-text>(i) a first endolysin or a first domain, both having a first enzymatic activity, the enzymatic activity being at least one or more of the following: N-acetyl-b-D-muramidase (lysozyme, lytic transglycosylase), N-acetyl-b-D-glucosaminidase, N-acetylmuramoyl-L-alanine amidase, L-alanoyl-D-glutamate (LD) endopeptidase, c-D-glutamyl-meso-diaminopimelic acid (DL) peptidase, L-alanyl-D-iso-glutaminyl-meso-diaminopimelic acid (D-Ala-m-DAP) (DD) endopeptidase, or m-DAP-m-DAP (LD) endopeptidase; and</claim-text>
<claim-text>(ii) at least one peptide stretch fused to the N- or C-terminus of the endolysin having the first enzymatic activity or the domain having the first enzymatic activity, wherein the peptide stretch is selected from the group consisting of synthetic amphipathic peptide, synthetic cationic peptide, synthetic polycationic peptide, synthetic hydrophobic peptide, synthetic antimicrobial peptide (AMP) or naturally occurring AMP; and</claim-text></claim-text>
<claim-text>(b) a second fusion protein including
<claim-text>(i) a second endolysin or a second domain, both having a second enzymatic activity, the enzymatic activity being at least one or more of the following: lipolytic activity, cutinase, mycolarabinogalactanesterase, or alpha/beta hydrolase; and</claim-text>
<claim-text>(ii) at least one peptide stretch fused to the N- or C-terminus of the endolysin having a second enzymatic activity or the domain having the second enzymatic activity, wherein the peptide stretch is selected from the group consisting of synthetic amphipathic peptide, synthetic cationic peptide, synthetic polycationic peptide, synthetic hydrophobic peptide, synthetic antimicrobial peptide (AMP) or naturally occurring AMP;</claim-text></claim-text></claim-text>
<claim-text>b) incubating the sample for a distinct period, and<!-- EPO <DP n="91"> --></claim-text>
<claim-text>c) isolating the mycobacterial lysate resulting from step b) thereby obtaining the mycobacterial lysate.</claim-text></claim-text></claim><claim id="c-en-0002" num="0002"><claim-text>The method according to claim 1, wherein the <i>Mycobacterium species</i> is selected from the group consisting of <i>Mycobacterium tuberculosis, Mycobacterium microti, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium canettii, Mycobacterium pinnipedii, Mycobacterium caprae, Mycobacterium mungi, Mycobacterium leprae, Mycobacterium ulcerans, Mycobacterium xenopi, Mycobacterium shottsii, Mycobacterium avium, Mycobacterium avium subsp. paratuberculosis, Mycobacterium paratuberculosis, Mycobacterium intracellulare, Mycobacterium smegmatis, Mycobacterium kansasii, Mycobacterium terrae, Mycobacterium nonchromogenicum, Mycobacterium gordonae, and Mycobacterium triviale.</i></claim-text></claim><claim id="c-en-0003" num="0003"><claim-text>The method according to claim 1 or 2, wherein step c) comprises High Performance Liquid chromatography (HPLC), Fast protein liquid chromatography (FPLC), filtration techniques, field flow fractionation, centrifugation or other techniques known as state in the art for the separation of biomolecules from bacterial lysates.</claim-text></claim><claim id="c-en-0004" num="0004"><claim-text>The method according to any one of the claims 1 to 3, wherein the first fusion protein of the composition exhibits an amino acid sequence selected from the group consisting SEQ ID NO:29, 31, 33, 35, 37, 39, and 41, and wherein the second fusion of the composition protein exhibits an amino acid sequence selected from the group consisting SEQ ID NO:43, 45, 47, 49, 51, 53, and 55.</claim-text></claim><claim id="c-en-0005" num="0005"><claim-text>A mycobacterial lysate prepared by degrading mycobacteria obtained by a method according to any one of the claims 1 to 4.</claim-text></claim><claim id="c-en-0006" num="0006"><claim-text>A vaccine composition for preventing a disease caused by a <i>Mycobacterium species</i> comprising the mycobacterial lysate according to claim 5.</claim-text></claim><claim id="c-en-0007" num="0007"><claim-text>The vaccine composition according to claim 6 further comprising an adjuvant and/or a pharmaceutical acceptable carrier.<!-- EPO <DP n="92"> --></claim-text></claim><claim id="c-en-0008" num="0008"><claim-text>An antibody or an antibody fragment generated by the administration of the mycobacterial lysate according to claim 5 or the vaccine composition according to any one of the claims 6 or 7 to a subject.</claim-text></claim><claim id="c-en-0009" num="0009"><claim-text>Antibody according to claim 8, wherein the antibody monoclonal or polyclonal.</claim-text></claim><claim id="c-en-0010" num="0010"><claim-text>A pharmaceutical composition comprising the antibody or antibody fragment according to claims 8 or 9 for use in preventing or treating an infectious disease caused by a <i>Mycobacterium species.</i></claim-text></claim></claims><search-report-data><doc-page id="srep0001" file="srep0001.tif" wi="159" he="233" type="tif"/><doc-page id="srep0002" file="srep0002.tif" wi="157" he="233" type="tif"/></search-report-data><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
